Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis (Q44830835)

6 December 2017

Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis (English)

1 reference

6 December 2017

1 reference

2

1 reference

6 December 2017

6

Lazaros I Sakkas

1 reference

6 December 2017

Ioannis Alexiou

1

1 reference

6 December 2017

Athanasios Koutroumpas

series ordinal

3

1 reference

6 December 2017

Anastasia Kontogianni

series ordinal

4

1 reference

6 December 2017

Katerina Theodoridou

series ordinal

5

1 reference

6 December 2017

3 January 2008

1 reference

6 December 2017

Clinical Rheumatology

1 reference

6 December 2017

27

1 reference

6 December 2017

511-513

1 reference

6 December 2017

4

1 reference

Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis

6 December 2017

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10067-007-0800-1

HLA class II sequence polymorphisms and susceptibility to rheumatoid arthritis in Greeks. The HLA-DR beta shared-epitope hypothesis accounts for the disease in only a minority of Greek patients

21 January 2018

1 reference

12 December 2020

HLA-DRB1* genotypes in Greek rheumatoid arthritis patients: association with disease characteristics, sex and age at onset.

1 reference

12 December 2020

Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis

1 reference

12 December 2020

Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations

1 reference

12 December 2020

Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark.

1 reference

12 December 2020

The HLA–DRB1 shared epitope alleles are primarily a risk factor for anti–cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis

1 reference

12 December 2020

Factors associated with the development of vasculitis in rheumatoid arthritis: results of a case-control study

1 reference

12 December 2020

Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement

1 reference

12 December 2020

Anti-cyclic citrullinated peptide (CCP) antibodies in patients with long-standing rheumatoid arthritis and their relationship with extra-articular manifestations

1 reference

12 December 2020

Use and significance of anti-CCP autoantibodies in rheumatoid arthritis

1 reference

12 December 2020

Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression

1 reference

12 December 2020

A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination

1 reference

12 December 2020

Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis

1 reference

12 December 2020

Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years

1 reference

12 December 2020

Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis

1 reference

12 December 2020

Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment

1 reference

12 December 2020

10.1007/S10067-007-0800-1

Identifiers

DOI

1 reference

6 December 2017

1 reference